Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playtex Q3

This article was originally published in The Rose Sheet

Executive Summary

Preliminary guidance anticipates net sales will increase 3%-4% in 2004, with firm's sun care division achieving similar results, Playtex CFO Glenn Forbes predicts during company's Q3 sales and earnings announcement Oct. 28. Playtex' sun care sales were "minimal" in the quarter at $2.3 mil., firm says. Company's net sales decreased 7.1% to $150.1 mil., while net earnings were down 64.7% to $3.13 mil. However, Playtex is optimistic launches next year will restore growth. These include revamped Kids product range with an SPF 50 extension, Suntanicals additions such as SPF 30 sunscreen and after sun lotion, and Surf SPF 30 waterproof sunblock (1"The Rose Sheet" Oct. 20, 2003, Marketing In Brief). Playtex expects the launch of Beyond Tampons,which begin shipping in Q1,to fill a niche in the feminine care market, and benefit sales...

You may also be interested in...



Commission Regulatory Advice For COVID-19 Medtech Sector Entrants Amid Counterfeit Concerns

A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Commission’s One-Year MDR Delay Text Contains EU-Wide Derogation Proposals Too

The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.

UsernamePublicRestriction

Register

RS011640

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel